CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the CE mark approval of its next-generation LED-based illumination device, or the INT200, for the INTERCEPT Blood System for platelets and plasma under the European Union (EU) Medical Device Regulation (MDR). This approval allows Cerus to market the INT200 throughout the EU and in other regions that recognize the...
Cerus Corporation (NASDAQ:CERS ) Q4 2024 Earnings Call February 20, 2025 4:30 PM ET Company Participants Noopur Liffick - Investor Relations Obi Greenman - President and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Carol Moore - Senior Vice President Conference Call Participants Joshua Jennings - TD Cowen Jacob Johnson - Stephens. Ross ...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for its full year and fourth quarter ended December 31, 2024. Recent highlights include: Total revenue for full-year 2024 and fourth quarter 2024 was comprised of (in thousands, except %): Three Months Ended Twelve Months Ended December 31, Change December 31, Change Un...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of Cerus' management are scheduled to present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, at 11:10 a.m. EST. A live webcast of the fireside chat will be available via the following link. A replay will be available for 90 days after the event. ABOUT CERUS Cerus Corporatio...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2024 financial results will be released on Thursday, February 20, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a ...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2024 and provided product revenue guidance for full-year 2025. The Company expects its preliminary full-year 2024 product revenue to be $180.3 million, exceeding the Company's 2024 product revenue guidance range of $177-$179 million. Included in the...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences. Management plans to participate in the Stifel 2024 Healthcare Conference on Monday, November 18th at 4:10 PM ET, and will attend the Craig-Hallum Alpha Select Conference on Tuesday, November 19th. A live webcast of the Stifel 2024 Healthcare Conference will...
Cerus Corporation (NASDAQ:CERS ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Jessica Hanover - VP, Corporate Affairs Obi Greenman - President & CEO Vivek Jayaraman - COO Kevin Green - CFO Conference Call Participants Matthew Park - Cantor Fitzgerald Colin Wells - Stifel Jacob Johnson - Stephens Joshua Jennings - TD Cowan Vidyun Bais - BTIG William Bonello -...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.